Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioCryst Pharma Q3 Adj. EPS $0.16 Beats $0.04 Estimate, Sales $159.395M Miss $162.974M Estimate

Author: Benzinga Newsdesk | November 03, 2025 07:00am
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.04 by 357.14 percent. This is a 328.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $159.395 million which missed the analyst consensus estimate of $162.974 million by 2.20 percent. This is a 36.14 percent increase over sales of $117.085 million the same period last year.

Posted In: BCRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist